Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0T2IA
|
||||
| Former ID |
DAP000298
|
||||
| Drug Name |
Dapiprazole
|
||||
| Synonyms |
Dapiprazol; Dapiprazolum; Dapirazol; Dapirazolum; Glamidolo; Remydrial; Reversil; Dapiprazol [German]; Dapiprazole [INN]; Dapiprazole (INN); Dapirazol [INN-Spanish]; Dapirazolum [INN-Latin]; Rev-Eyes; Rev-Eyes (TN); S-Triazolo(4,3-a)pyridine, 5,6,7,8-tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-,hydrochloride; 3-(2-(4-(2-methylphenyl)-1-piperazinyl)ethyl)-5,6,7,8,-tetrahydro-1,2,4-triazolo(4,3-a)pyridine hydrochloride; 3-[2-[4-(2-methylphenyl)piperazin-1-yl]ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine; 3-{2-[4-(2-methylphenyl)piperazin-1-yl]ethyl}-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine; 5,6,7,8-Tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-s-triazolo(4,3-a)pyridine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Glaucoma [ICD9: 365; ICD10:H40-H42] | Approved | [1] | ||
| Therapeutic Class |
Ophthalmologicals
|
||||
| Company |
Abbott Laboratories
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H27N5
|
||||
| InChI |
InChI=1S/C19H27N5/c1-16-6-2-3-7-17(16)23-14-12-22(13-15-23)11-9-19-21-20-18-8-4-5-10-24(18)19/h2-3,6-7H,4-5,8-15H2,1H3
|
||||
| InChIKey |
RFWZESUMWJKKRN-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 72822-12-9
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
6823468, 10047683, 14801660, 36077438, 46508859, 50057655, 56394877, 57352743, 76691712, 85209404, 96024473, 111634408, 124963552, 126665781, 129123536, 134337610, 135012447, 137004989, 137939947, 143188853, 160963646, 164788310, 178103730, 179151036, 184533547, 184545929, 198943087, 223679991, 223702357, 226517331, 241132118, 241382806, 251916859, 251918098, 252347834, 252425541
|
||||
| ChEBI ID |
ChEBI:51066
|
||||
| SuperDrug ATC ID |
S01EX02
|
||||
| SuperDrug CAS ID |
cas=072822129
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 2 | Effect of ibopamine on aqueous humor production in normotensive humans. Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4853-8. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.